论文部分内容阅读
目的:评价曲美他嗪联合常规药物治疗冠心病不稳定性心绞痛的临床疗效。方法:将同期104例不稳定性心绞痛患者随机分为对照组(52例)和治疗组(52例)。对照组给予抗血小板药物、抗凝药物、β受体阻滞剂、硝酸酯类、钙离子阻滞剂、血管紧张素转换酶抑制剂及调脂药物治疗。治疗组在常规治疗基础上加用曲美他嗪20mg,3次/d,口服,治疗4周后观察两组治疗后临床疗效及心电图变化。结果:总有效率治疗组92.3%,对照组71.1%;心电图改善率分别为67.3%和32.6%。结论:联合应用曲美他嗪对冠心病不稳定性心绞痛安全有效。
Objective: To evaluate the clinical efficacy of trimetazidine combined with conventional drugs in the treatment of unstable angina pectoris. Methods: 104 patients with unstable angina at the same period were randomly divided into control group (52 cases) and treatment group (52 cases). The control group was given antiplatelet drugs, anticoagulants, β blockers, nitrates, calcium blockers, angiotensin converting enzyme inhibitors and lipid-lowering drugs. The treatment group was treated with trimetazidine 20 mg three times a day on the basis of conventional treatment. After 4 weeks of treatment, the clinical efficacy and electrocardiogram changes of the two groups were observed. Results: The total effective rate was 92.3% in the treatment group and 71.1% in the control group. The improvement rate of electrocardiogram was 67.3% and 32.6% respectively. Conclusion: The combination of trimetazidine is safe and effective in patients with coronary heart disease and unstable angina pectoris.